Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Analytical Scientist
  • Explore

    Explore

    • Latest
    • News & Research
    • Trends & Challenges
    • Keynote Interviews
    • Opinion & Personal Narratives
    • Product Profiles
    • App Notes

    Featured Topics

    • Mass Spectrometry
    • Chromatography
    • Spectroscopy

    Issues

    • Latest Issue
    • Archive
  • Topics

    Techniques & Tools

    • Mass Spectrometry
    • Chromatography
    • Spectroscopy
    • Microscopy
    • Sensors
    • Data and AI

    • View All Topics

    Applications & Fields

    • Clinical
    • Environmental
    • Food, Beverage & Agriculture
    • Pharma and Biopharma
    • Omics
    • Forensics
  • People & Profiles

    People & Profiles

    • Power List
    • Voices in the Community
    • Sitting Down With
    • Authors & Contributors
  • Business & Education

    Business & Education

    • Innovation
    • Business & Entrepreneurship
    • Career Pathways
  • Events
    • Live Events
    • Webinars
  • Multimedia
    • Video
Subscribe
Subscribe

False

The Analytical Scientist / Issues / 2017 / Sep / The Analysis of Residual Solvents in Pharmaceutical Products Using GC-VUV and Static Headspace
Pharma and Biopharma Chromatography Gas Chromatography Sponsored

The Analysis of Residual Solvents in Pharmaceutical Products Using GC-VUV and Static Headspace

09/14/2017 1 min read

Sponsored By

Share

Volatile organic compounds are used in pharmaceutical manufacturing during the production of drug substances, pharmaceutical additives, and drug products. Known also as residual solvents, they account for 50-90 percent of mass in typical pharmaceutical operations and represent most of the process toxicity. Testing for the presence of these solvents, therefore, is critical for patient safety. Testing commonly follows United States Pharmacopeia (USP) Method <467> guidelines, which suggest a gas chromatography (GC) runtime of 60 min. In addition, it is recommended that Class 1 and 2 solvents be identified and quantitated by complementary methods utilizing different stationary phase selectivity when solvents are found to meet or exceed the permitted daily exposure (PDE) concentration limits. In this unique application, a gas chromatography–vacuum ultraviolet (GC-VUV; VUV Analytics VGA-100) method was developed to significantly reduce the analytical bottleneck involved in the testing of residual solvents. Experiments were undertaken to demonstrate the chromatographic capabilities of GC-VUV when applied to residual solvent analysis using model pharmaceutical matrices such as generic throat spray. Samples were prepared by mixing 2-mL of water with 25-100 mg/mL of pharmaceutical product and spiking Class 2 Solvent Mix A and B (Restek) to meet the desired concentration limits.  The total GC runtime was set to eight minutes and used throughout the GC-VUV residual solvent application.

Figure 1. Compressed gas chromatogram showing Class 2 residual solvents separated and identified in less than eight minutes. The typical runtime for the USP 467 method is 60 min.

This method for residual solvent analysis was shown to offer a few key advantages over USP Method 467 experimental conditions. First, VUV absorbance spectra provided authoritative solvent identification as well as compound quantitation. Second, chromatographic compression was possible without any loss of data quality. Runtimes of 8 minutes or less – a 5× or greater reduction – were shown to be sufficient for the analysis of Class 1 and 2 residual solvents. Third, different residual solvent classes could be analyzed in a single run. The VUV detector delivered a linear, highly reproducible response at concentrations ranging from 2× to 0.1× the Class 1 and 2 PDE detection, and the ability to deconvolve analyte co-elution. In summary: the analysis of residual solvents by GC-VUV delivers a single method for the identification and quantitation of toxic compounds in pharmaceutical products.

>> Download the full Application Note as PDF

Newsletters

Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

False

Advertisement

Recommended

False

Related Content

Loading the Molecular Dice
Pharma and Biopharma
Loading the Molecular Dice

December 12, 2024

2 min read

How a framework for controlling molecular reactions at the atomic scale has potential implications for nanotechnology, pharmaceutical synthesis, and clean energy research

CD-MS: To Megadalton and Beyond
Pharma and Biopharma
CD-MS: To Megadalton and Beyond

October 1, 2024

10 min read

Charge-detection mass spectrometry (CD-MS) has extended the range of MS to gigadalton-sized viruses and polymers; and with a commercial instrument in development and exciting new applications in complex protein mixtures, maturity beckons

New NMR Technique Enables Direct Detection of Molecular Chirality
Pharma and Biopharma
New NMR Technique Enables Direct Detection of Molecular Chirality

October 1, 2024

1 min read

Researchers develop an NMR method to distinguish between enantiomers without the need for chiral agents

Mass Spec Imaging Meets Proteomics
Pharma and Biopharma
Mass Spec Imaging Meets Proteomics

October 2, 2024

2 min read

Researchers combine tissue imaging with proteomics to shed light on the neurotoxic effects associated with HIV medication Efavirenz treatment

False

The Analytical Scientist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.